In Section C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment till ailment progression or perhaps the individuals are not able to tolerate the study drugs. For all flow cytometry experiments, 10,000 cells per replicate have been analyzed, https://alanx332pbm6.blogacep.com/profile